Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast05 in PD-L1-positive unresectable locally recurrent or metastatic triple-negative breast cancer
CTR20233975Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, durvalumab, pembrolizumab, paclitaxel, gemcitabine in triple-negative breast cancer (TNBC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2024; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20233975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233975.